Abstract
Since one of the attractions of gene therapy in the heart is the implantation of genetically modified cultured cells, we employed genetically modified myocytes transfected with FITC-labeled oligodeoxynucleotides (ODN) and β-galactosidase gene in this study, to investigate the cellular localization and fate of grafted myocytes in the heart. In addition, we examined the feasibility of myocytes grafting into a myocardial infarction model. Delivery of FITC-labeled ODN with the HVJ–liposome method resulted in sustained fluorescence as compared to direct transfer of ‘naked’ ODN. Interestingly, implantation of cardiac myocytes transfected with FITC-labeled ODN ex vivo by the HVJ–liposome method resulted in sustained fluorescence for at least 1 week in the noninfarcted area, whereas little fluorescence was detected in the area of infarction. This observation was confirmed by measurement of fluorescence, which showed significantly higher levels in the noninfarcted area than the infarcted area. Positive staining for β-galactosidase protein was also clearly observed 7 days after grafting of transfection of the β-galactosidase gene, while no staining was detected in grafted myocytes in control rats. Survival of implanted genetically modified cardiac myocytes in the noninfarcted, but not infarcted area, provides new information for the local delivery of recombinant molecules to the heart using gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aoki, M., Morishita, R., Higaki, J. et al. Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the β-galactosidase gene in the noninfarcted area, but not the myocardial infarcted area. Gene Ther 4, 120–127 (1997). https://doi.org/10.1038/sj.gt.3300361
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300361
Keywords
This article is cited by
-
Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease
Clinical and Experimental Nephrology (2007)
-
Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model
Gene Therapy (2005)
-
Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle
Gene Therapy (2002)
-
Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates
Gene Therapy (2001)
-
Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets
Gene Therapy (2000)